Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Epoetin alfa plus lenograstim costly, no QOL benefit in anaemia

    • 8 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Epoetin alfa plus lenograstim costly, no QOL benefit in anaemia. Pharmacoecon. Outcomes News 459, 14 (2004). https://doi.org/10.2165/00151234-200404590-00038

    Download citation

    Keywords

    • Supportive Care
    • Erythropoietin
    • Myelodysplastic Syndrome
    • Study Endpoint
    • Refractory Anaemia